Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-01
2008-01-01
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S309000
Reexamination Certificate
active
07314937
ABSTRACT:
The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases
REFERENCES:
patent: 2810719 (1957-10-01), Moore et al.
patent: 4963563 (1990-10-01), DeBernardis et al.
patent: 6316475 (2001-11-01), Bennani et al.
patent: 6610721 (2003-08-01), Andersen et al.
patent: 2001/0049367 (2001-12-01), Bennani et al.
patent: 2002/0035103 (2002-03-01), Bennani et al.
patent: 2002/0111340 (2002-08-01), Bennani et al.
patent: 2002/0137931 (2002-09-01), Bennani et al.
patent: 2002/0169188 (2002-11-01), Cowart et al.
patent: 2635276 (1977-02-01), None
patent: 0114410 (1984-08-01), None
patent: 0237781 (1987-09-01), None
patent: 0982300 (2000-03-01), None
patent: 1113007 (2001-07-01), None
patent: 1283199 (2003-02-01), None
patent: WO-96/11192 (1996-04-01), None
patent: WO-99/19293 (1999-04-01), None
patent: WO-00/06254 (2000-02-01), None
patent: WO-00/64884 (2000-04-01), None
patent: WO00/42036 (2000-07-01), None
patent: WO-01/66534 (2001-09-01), None
patent: WO-02/06223 (2002-01-01), None
patent: WO-02/12190 (2002-02-01), None
patent: WO-02/40456 (2002-05-01), None
patent: WO-02/40461 (2002-05-01), None
patent: WO-02/074758 (2002-09-01), None
patent: WO-03/064411 (2003-08-01), None
Wegner, CA 105:42726, Archiv der Pharmazie (Weinheim, German7), 1986, vol. 319(1), pp. 85-88, abstract only.
Paul J. Gilligan et al., Novel Piperidine • Receptor Ligands as Potential Antipsychotic Drugs, J. Med. Chem., 1992, 4344-4361, vol. 35.
Von E. Rudinger-Adler et al., Synthese einiger Phenoxymethylphenyl-Derivate mit lokalanasthetischer Wirkung, Arzneim.-Forsch. /Drug Res, 1979, 591-594, vol. 29, No. 4.
Severine Morisset et al., High constitutive activity of native H3receptors regulates histamine neurons in brain, Nature, 860-864, Dec. 14, 2000, vol. 408.
Ian D. Linney et al., Design, Synthesis, and Structure-Activity Relationships of Novel Non-Imidazole Histamine H3Receptor Antagonists, J. Med. Chem., 2362-2370, 2000, vol. 43.
Henk Van Der Goot et al., Selective ligands as tools to study histamine receptors, Eur. J. Med. Chem., 5-20, 2000, vol. 35.
Holger Stark et al., Analogues and Derivatives of Ciproxifan, a Novel Prototype for Generating Potent Histamine H3-Receptor Antagonists, Bioorganic & Medicinal Chemistry Letters 2379-2382, 2000, vol. 10.
Albert D. Windhorst et al., Characterization of the Binding Site of the Histamine H3Receptr. 2. Synthesis, in Vitro Pharmacology, and QSAR of a Series of Monosubstituted Benzyl Analogues of Thioperamide, J. Med. Chem. 1754-1761, 2000, vol. 43.
Astrid Sasse et al., New Histamine H3-Receptor Ligands of the proxifan Series: Imoproxifan and Other Sleective Antagonists with High Oral in Vivo Potency, J. Med. Chem., 3335-3343, 2000, vol. 43.
Holger Stark et al., Novel Histamine H3-Receptor Antagonists with Carbonyl-Substituted 4-(3- (Phenoxy)propyl)-1H-imidazole Structures like Ciproxifan and Related Compounds, J. Med. Chem., 3987-3994, 2000, vol. 43.
Astrid Sasse et al., (Partial) Agonist/Antagonist properties of Novel Diarylalkyl Carbamates on Histamine H3Receptors, Bioorganic & Medicinal Chemistry, 1139-1149, 2000, vol. 8.
Astrid Sasse et al., Benzophenone erivatives and Related Compounds as Potent Histamine H3-Receptor Antagonists and Potential PET/SPECT Ligands, Arch. Pharm. Pharm. Med. Chem., 45-52, 2001, vol. 334.
Iwan J. P. De Esch et al., Development of a Pharmacophore Model for Histamine H3Receptor Antagonists, Using the Newly Developed Molecular Modeling Program SLATE, J. Med. Chem., 1666-1674, 2001, vol. 44.
Galina Meier et al., Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists, European Journal of Pharmaceutical Sciences, 249-259, 2001, vol. 13.
Vijay K. Agrawal et al., QSAR Studies on Acylated Histamine Derivatives, Bioorganic & Medicinal Chemistry, 2787-2792, 2001, vol. 9.
Jean-Charles Schwartz et al., Application of genomics to drug design: the example of the histamine H3receptor, European Neuropsychopharmacology, 441-448, 2001, vol. 11.
Joachim Apelt et al., Development of a New Class of Nonimidazole Histamine H3Receptor Ligands with Combined Inhibitory HistamineN-Methyltransferase Activity, J. Med. Chem., 1128-1141, 2002, vol. 45.
Sven Grabmann et al., Progress in the Proxifan Class: Heterocyclic Congeners as Novel Potent and Selective Histamine H3-Receptor Antagonists, European Journal of Pharmaceutical Sciences, 367-378, 2002, vol. 15.
Shigeki Habaue et al.; Anionic Polymerization ofo-Substituted Styrene Derivatives: Control of Reactivity and Sterochemistry by Aminomethyl Group, Journal of Polymer Science: Part A: Polymer Chemistry, 2000, 4088-4094, vol. 38.
Beavers Lisa Selsam
Gadski Robert Alan
Hipskind Philip Arthur
Lindsley Craig William
Lobb Karen Lynn
Eli Lilly and Company
Seaman D. Margaret
Wood Dan L.
LandOfFree
Non-imidazole aryl alkylamines compounds as histamine H3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-imidazole aryl alkylamines compounds as histamine H3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-imidazole aryl alkylamines compounds as histamine H3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2768703